表紙
市場調查報告書

神經膠質細胞株衍生神經滋養因子:開發中產品分析

Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 398835
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
神經膠質細胞株衍生神經滋養因子:開發中產品分析 Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 59 Pages
簡介

本報告提供以神經膠質細胞株衍生神經滋養因子為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

神經膠質細胞株衍生神經滋養因子 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • NsGene A/S
  • UniQure N.V.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2381TDB

Summary:

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 3 and 10 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Cardiovascular which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Glaucoma, Ischemic Stroke, Keratoconjunctivitis Sicca (Dry Eye), Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy), Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Peripheral Nerve Injury, Radiculopathy, Retinal Degeneration and Retinitis Pigmentosa (Retinitis).

The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
  • The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development
  • Biogen Inc
  • Copernicus Therapeutics Inc
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Junaxo Inc
  • Kai Nuo Bio Sci Co Ltd
  • Kolon Life Science Inc
  • Lauren Sciences LLC
  • Neuroptika Inc
  • Stem Cell Medicine Ltd
  • Treeway BV
  • UniQure NV
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles
  • AMT-090 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Neurodegenerative Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis and Retinitis Pigmentosa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-812 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KLS-2031 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LAUR-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LAUR-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NRO-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Protein to Activate GDNF for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • smilagenin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ST-502 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TW-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products
  • Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 17, 2020: Neuroptika enrols first patient for dry eye disease trial
  • Apr 30, 2019: Neuroptika announces positive data from NRO-1 phase 1 clinical trial
  • Mar 11, 2019: Kolon gets FDA nod for testing gene therapy for neuropathic pain
  • Dec 26, 2018: Neuroptika, Spun Out from Senju Pharmaceutical launches to develop novel regenerative treatment
  • Dec 26, 2018: Neuroptika, spun out from Senju Pharmaceutical launches to develop novel regenerative treatment
  • Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients
  • Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association
  • Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane
  • Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane
  • Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis
  • Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease
  • Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis
  • Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study
  • Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis
  • Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Biogen Inc, H1 2020
  • Pipeline by Copernicus Therapeutics Inc, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by GlaxoSmithKline Plc, H1 2020
  • Pipeline by Junaxo Inc, H1 2020
  • Pipeline by Kai Nuo Bio Sci Co Ltd, H1 2020
  • Pipeline by Kolon Life Science Inc, H1 2020
  • Pipeline by Lauren Sciences LLC, H1 2020
  • Pipeline by Neuroptika Inc, H1 2020
  • Pipeline by Stem Cell Medicine Ltd, H1 2020
  • Pipeline by Treeway BV, H1 2020
  • Pipeline by UniQure NV, H1 2020
  • Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020